P. Tresca

发表

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

V. Diéras, A. van der Gaast, H. Fontaine, 2014, British Journal of Cancer.

Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents

Xavier Paoletti, Wulfran Cacheux, W. Cacheux, 2010, Targeted Oncology.

Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients

B. Winterhalter, S. Kerpel-Fronius, A. Hanauske, 2004, Investigational New Drugs.

Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.

M. Campone, G. Romieu, F. Bidard, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Fine‐needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next‐generation sequencing in cancer patients included in the SHIVA02 trial

P. Gestraud, O. Mariani, A. Vincent-Salomon, 2020, Molecular oncology.

Ifosfamide (IFO)+vinorelbine (VRL) as treatment for advanced, non operable non small cell lung cancer (NSCLC)

S. Kerpel-Fronius, J. Pawel, P. Tresca, 1994 .

Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy

V. Servois, X. Paoletti, M. Sablin, 2021, Drugs in R&D.

Human pharmacokinetics of N‐l‐leucyl‐doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities

J. Robert, M. Marty, D. Belpomme, 1992, Clinical pharmacology and therapeutics.

Pharmacokinetic (PK) Interactions between Lapatinib (L) and Vinorelbine (VNR) in a Phase I Study in Locally Advanced or Metastatic Breast Cancer (LAMBC) Patients(Pts) Overexpressing HER2. GEP-01 – A Study of the FNCLCC-Group of Early Phase Trials.

J. Bonneterre, P. Fumoleau, V. Diéras, 2009 .

Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method.

M. Espié, M. Marty, J. Pierga, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor.

J. Schellens, M. Scheulen, V. Diéras, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial

N. Girard, I. Bièche, F. André, 2021, ESMO open.

Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis.

S. Taillibert, O. Trédan, V. Diéras, 2018, European journal of cancer.

Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents

V. Servois, X. Paoletti, V. Diéras, 2012, British Journal of Cancer.

Relevance of a molecular tumour board (MTB) for patients’ enrolment in clinical trials: experience of the Institut Curie

O. Mariani, A. Vincent-Salomon, R. Rouzier, 2018, ESMO Open.

Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)

I. Bièche, M. Sablin, M. Kamal, 2021, JCO precision oncology.

Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.

S. Vacher, I. Bièche, N. Servant, 2019, European journal of cancer.

Sustained Tumor Control With MAPK Inhibition in BRAF V600–Mutant Adult Glial and Glioneuronal Tumors

K. Hoang-Xuan, F. Ducray, M. Sanson, 2021, Neurology.

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2

J. Bonneterre, P. Fumoleau, V. Diéras, 2012, British Journal of Cancer.

Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site

S. Rodenhuis, E. Barillot, A. Nicolas, 2020, British Journal of Cancer.

A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial

O. Mariani, A. Salomon, V. Servois, 2021, npj Precision Oncology.

Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.

M. Espié, M. Desilvio, H. Burris, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature.

Xavier Paoletti, X. Paoletti, V. Diéras, 2011, European journal of cancer.

An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

M. van Glabbeke, J. Armand, P. Fumoleau, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract OT3-4-06: Circulating tumor cells to guide the choice between chemotherapy and hormone therapy as first line treatment for hormone receptors positive metastatic breast cancer patients: the STIC CTC METABREAST trial

B. Asselain, F. Bidard, J. Pierga, 2012 .

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

J. Schellens, R. Rueger, M. Scheulen, 2012, Clinical Cancer Research.

Cancer Therapy: Clinical Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

J. Schellens, R. Rueger, M. Scheulen, 2012 .

[Study of vinorelbine (V) combined with hexamethylmelamine (H) (combination V-H) in adenocarcinoma of the ovary: results a phase I-IIA trial, NHO-88, of ARTAC "ovarian" group].

B. Coiffier, B. Roullet, T. Facchini, 1991, Bulletin du cancer.

From prospective biobanking to precision medicine: BIO-RAIDs – an EU study protocol in cervical cancer

Roman Rouzier, Philippe Hupé, Charlotte Ngo, 2015, BMC Cancer.

P1-06-12: Circulating Tumor Cells (CTC) Monitoring during Phase II Study with Lapatinib (L) and Capecitabine (C) in Patients with Brain Metastases from HER2−Positive (+) Metastatic Breast Cancer (MBC) before Whole Brain Radiotherapy (WBR): LANDSCAPE Study.

M. Campone, G. Romieu, F. Bidard, 2011 .

Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis.

S. Taillibert, O. Trédan, V. Diéras, 2018, European journal of cancer.

Cancer Therapy: Clinical Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

J. Schellens, R. Rueger, M. Scheulen, 2012 .